期刊
JOURNAL OF HEPATOLOGY
卷 56, 期 2, 页码 320-325出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2011.05.032
关键词
Hepatitis C virus; Antiviral therapy; Pegylated-interferon
资金
- Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [MRP 05315-2]
- Schering-Plough Corporation (Kenilworth, NJ, USA)
- Public Health Service [DK56338]
- NIH [K24DK078154-03]
Background & Aims: Antiviral treatment for hepatitis C virus (HCV) has high efficacy rates for achieving sustained viral response (SVR) in randomized controlled trials (RCTs) (40-80%); however, it can be lower in community-based practice settings. We wanted to determine the effectiveness of HCV treatment in Veterans Administration (VA) hospitals nationwide. Methods: Using the nationwide VA HCV Clinical Case Registry (CCR), we examined a cohort of veterans who had HCV viremia between 2000 and 2005 and identified patients who received pegylated-interferon (PEG-INF) and ribavirin. The duration of treatment and proportion of patients completing treatment was calculated. The effectiveness of treatment was measured as the proportion of patients who achieved SVR (negative viremia at least 12 weeks after the end of treatment) in the entire cohort, and among patients who initiated and completed treatment. Results: We identified 99,166 patients with HCV viremia. Of those, 11.6% received PEG-INF with ribavirin and 6.4% completed treatment. Contraindications were present in 57.2% of the patients that did not receive treatment. SVR was documented in 39.9% and 58.3% of patients who completed treatment; 23.6% and 50.6% of patients who initiated treatment; and 3.9% and 11.2% of the entire HCV cohort for genotype 1 or 4 and 2 or 3, respectively. Overall, only 3.5% of the entire HCV viremic cohort had a documented SVR. Conclusions: Treatment effectiveness for HCV is low. In addition to fixed factors, such as race and virus genotype, the drop in effectiveness is due to low rates of antiviral treatment initiation and treatment completion. Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据